Simian immunodeficiency virus macaque models of HIV latency.
OBJECTIVE
This review will focus on recent developments in several nonhuman primate models of AIDS. These models are being used to address viral latency and persistence during antiretroviral therapy in studies that are not feasible in humans.


RESULTS
Further characterization of the various macaque models of AIDS has demonstrated that several aspects of viral persistence during antiretroviral therapy model HIV-1 infection in humans, including viral decay kinetics. Widespread distribution of viral RNA and viral DNA has been detected in many tissue organs. In addition, the brain has been identified as a site of persistent viral DNA.


CONCLUSIONS
The macaque models of AIDS are well suited for addressing viral persistence during antiretroviral therapy, including viral latency, residual replication, and tissue organ distribution.
Center for Comparative Medicine, University of California, Davis, California, USA.
Jesse D
JD
Deere
Raymond F
RF
Schinazi
Thomas W
TW
North
D000818:Animals; D004195:Disease Models, Animal; D015658:HIV Infections / Q000821:virology; D006801:Humans; D008251:Macaca / Q000821:virology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000821:virology*; D015302:Simian Immunodeficiency Virus / Q000472:pathogenicity*; D017735:Virus Latency
JAMA. 2008 Aug 6;300(5):555-70
18677028
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7
9371822
PLoS Pathog. 2010 Jan 29;6(1):e1000748
20126442
J Virol. 2005 Jun;79(12):7349-54
15919889
Antiviral Res. 2010 Jan;85(1):159-75
19622373
PLoS One. 2010 Jul 23;5(7):e11640
20668516
Antimicrob Agents Chemother. 2004 Sep;48(9):3483-90
15328115
AIDS. 2009 Jun 19;23(10):1187-95
19455015
Nat Med. 1999 May;5(5):512-7
10229227
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4425-9
19255423
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73
9671771
Retrovirology. 2010 Mar 16;7:21
20233398
Antimicrob Agents Chemother. 2003 May;47(5):1756-9
12709355
J Virol. 2010 Mar;84(6):2913-22
20032180
Nature. 1995 Jan 12;373(6510):123-6
7816094
PLoS One. 2010 May 07;5(5):e10523
20479889
J Virol. 2005 Aug;79(15):9625-34
16014925
Science. 1995 Nov 17;270(5239):1197-9
7502044
Biochem Biophys Res Commun. 1995 Jun 26;211(3):850-6
7541200
AIDS Res Ther. 2009 Nov 05;6:23
19891783
J Virol. 2003 Oct;77(20):11212-9
14512569
J Virol. 2004 Dec;78(24):13553-61
15564466
J Clin Microbiol. 2003 Oct;41(10):4531-6
14532178
J Virol. 2007 Nov;81(22):12145-55
17855539
Science. 1997 Nov 14;278(5341):1295-300
9360927
PLoS Pathog. 2010 Jan 29;6(1):e1000747
20126441
Nature. 1997 May 8;387(6629):183-8
9144289
Retrovirology. 2009 Nov 04;6:101
19889213
J Infect Dis. 2010 Jul 1;202(1):161-70
20497048
Nat Med. 2000 Jul;6(7):757-61
10888923
J Clin Invest. 2000 Oct;106(7):839-45
11018071
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8210-4
7545297
J Virol. 2002 Jun;76(12):6083-92
12021341
J Virol. 2003 Apr;77(8):4938-49
12663799
J Virol. 2002 Jun;76(11):5803-6
11992009
Am J Pathol. 2010 Aug;177(2):777-91
20595631
Antivir Chem Chemother. 2009 Oct 19;20(2):63-78
19843977
J Virol. 2009 Sep;83(18):9247-57
19570871
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3879-84
18332425
AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):243-51
11177407